Dr Ashiwini Maratha

print version
'Dr Ashiwini Maratha' image

. Dr Maratha graduated from Osmania University, Hyderabad, India in 2004 with a BSc in Biotechnology and Bioinformatics, which included a featured project on molecular modelling of Heamophilus influenzae typeB. Successively she then completed a Masters in Molecular Biotechnology at Kakatiya University, Warangal, India in 2006, which involved a research internship at Centre for Cellular and Molecular Biology (CCMB), a premier scientific institution lead by Council of Scientific and Industrial Research of India. Here Dr Maratha developed a novel assay for screening thermostability of lipases, which gained her a university gold medal. Next, Dr Maratha took up a project research fellow position funded by Department of Biotechnology in CCMB from 2006 to 2007, where she investigated various disease resistant genes utilising mass scale DNA sequencing and mutation analysis.

Following this, Dr Maratha was awarded with Health Research Board (HRB) Ireland fellowship for PhD scholar's in Immunology for 2007-2011 at National University of Ireland Maynooth (NUIM). Where, her PhD focused on investigating innate immune signalling cascades in acute and chronic inflammatory disease pathologies namely Rheumatoid Arthritis (RA) and Osteoarthritis (OA). Her studies lead to the identification of key innate immune regulatory mechanisms and toll like receptors (TLRs) as potential therapeutic targets for OA and RA pathologies. Where in, ex-vivo validation of OA and RA specific TLRs as therapeutic targets, through pioneering TLR neutralisation studies in human synovial tissue explants and synovial fluid, was a highlight of her research.

Subsequently, Dr Maratha was employed through HRB postdoctoral research fellowship in 2011 at NUIM, focusing on exploring the role of TLRs in the pathogenesis of Type II Diabetes. Where, she worked with pre-diabetic and type II diabetic human samples and established a novel panel of inflammatory serum markers to measure type II diabetes associated complications. Dr Maratha then took up an Enterprise Ireland funded postdoctoral research position at UCD in 2012, and worked on a mechanistically anchored biomarker panel to predict outcome of node-negative breast cancer (OncoMasTR), as an integrated diagnostic solution for improved patient stratification.